ES2109683T3 - Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b. - Google Patents

Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b.

Info

Publication number
ES2109683T3
ES2109683T3 ES94911608T ES94911608T ES2109683T3 ES 2109683 T3 ES2109683 T3 ES 2109683T3 ES 94911608 T ES94911608 T ES 94911608T ES 94911608 T ES94911608 T ES 94911608T ES 2109683 T3 ES2109683 T3 ES 2109683T3
Authority
ES
Spain
Prior art keywords
pct
formula
thyomorfoline
gaba
morpholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94911608T
Other languages
English (en)
Inventor
Shen-Chun Kuo
David J Blythin
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2109683T3 publication Critical patent/ES2109683T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE EXPONEN COMPUESTOS DE FORMULA (I) DONDE: Y REPRESENTA CO{SUB.2}H, -CO{SUB.2}R{SUP.6}, -C(O)NHR{SUP.7}, -SO{SUB.2}H, SO{SUB.3}H, -SO{SUB.3}R{SUP.6}, -SO{SUB.2}NHR{SUP.7}, -C(O)N(OH)-R{SUP.8}, O UN GRUPO DE FORMULA (A), (B), (C), (D), O (E) O UNA SAL O SOLVENTE FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS; TAMBIEN SE EXPONEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS DE FORMULA (I). SE EXPONE ADEMAS UN METODO PARA TRATAR O PREVENIR LA DEPRESION RESPIRATORIA, ACCESOS EPILEPTICOS Y OTROS DESORDENES DEL SISTEMA NERVIOSO CENTRAL, Y PARA REFORZAR EL RESULTADO COGNITIVO, MEDIANTE LA ADMISTRACION DE UNA CANTIDAD EFICAZ DE UN COMPUESTO DE FORMULA (I).
ES94911608T 1993-03-26 1994-03-23 Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b. Expired - Lifetime ES2109683T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3858493A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ES2109683T3 true ES2109683T3 (es) 1998-01-16

Family

ID=21900746

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94911608T Expired - Lifetime ES2109683T3 (es) 1993-03-26 1994-03-23 Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b.

Country Status (14)

Country Link
US (1) US5929236A (es)
EP (1) EP0690850B1 (es)
JP (1) JP2778832B2 (es)
AT (1) ATE160143T1 (es)
AU (1) AU6408894A (es)
CA (1) CA2158952C (es)
DE (1) DE69406779T2 (es)
DK (1) DK0690850T3 (es)
ES (1) ES2109683T3 (es)
GR (1) GR3025950T3 (es)
IL (1) IL109111A (es)
TW (1) TW280817B (es)
WO (1) WO1994022843A1 (es)
ZA (1) ZA942090B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853626A1 (en) * 1995-09-07 1998-07-22 Novartis AG Substituted phosphinic compounds and their use as pharmaceuticals
WO1998028313A1 (en) * 1996-12-24 1998-07-02 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
NZ233503A (en) * 1989-05-15 1991-06-25 Janssen Pharmaceutica Nv Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法

Also Published As

Publication number Publication date
WO1994022843A1 (en) 1994-10-13
GR3025950T3 (en) 1998-04-30
IL109111A0 (en) 1994-06-24
IL109111A (en) 1999-07-14
ATE160143T1 (de) 1997-11-15
EP0690850A1 (en) 1996-01-10
DK0690850T3 (da) 1998-02-09
TW280817B (es) 1996-07-11
DE69406779D1 (en) 1997-12-18
EP0690850B1 (en) 1997-11-12
CA2158952C (en) 1999-05-18
JP2778832B2 (ja) 1998-07-23
CA2158952A1 (en) 1994-10-13
JPH08503229A (ja) 1996-04-09
AU6408894A (en) 1994-10-24
ZA942090B (en) 1994-09-26
US5929236A (en) 1999-07-27
DE69406779T2 (de) 1998-03-12

Similar Documents

Publication Publication Date Title
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
KR960703598A (ko) 신경 질환 치료제(agent for curing neurotic diseases)
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
ATE160143T1 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
RU94044454A (ru) Ингибитор аутоимунных заболеваний
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR950016760A (ko) 치질 치료제
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
BRPI0211025B8 (pt) um novo composto para o tratamento da impotência
DE69421457D1 (de) Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen
BR9807271A (pt) Tamoxifeno como terapia para reduzir diarréia induzida por cloridrato de irinotecano
ES2164234T3 (es) Fusacandinas antifungicas.
KR950016739A (ko) 강박관념 질환 및 소모성 질환을 억제하는 방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 690850

Country of ref document: ES